Get Connected:


Latest News

CMS Outlines Coverage of Next Generation Sequencing for Cancer
FoundationOne CDx is the first-of-a-kind comprehensive companion diagnostic test for solid tumors. 
Top news of the day from across the health care landscape.
Participants receiving semaglutide lost significantly more weight than those receiving placebo after 1 year. 
Hydroxyurea tablets previously received priority review and orphan drug designations from the FDA.
Top news of the day from across the health care landscape.
Reducing financial barriers may increase the use of evidence-based treatments and improve adherence to medications.
Top news of the week from The American Journal of Pharmacy Benefits.
A look at last week's top stories in the world of pharmacy.
View More >

From the Journals

New proposed rules for the Medicare Part D drug program could affect the manner in which pharmacy benefit managers administer the program and could impact profitability.
Healthcare stakeholders must evaluate how to use resources more efficiently as it has become clear that driving down prices in one segment of care has not improved medical outcomes for the majority of patients.
This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.
An estimation and comparison of the cost of home phototherapy versus biologics over a 3-year time horizon in patients with moderate-to-severe plaque psoriasis.
The study found no mean difference in all-cause healthcare costs for patients with newly diagnosed nonvalvular atrial fibrillation initiating treatment with dabigatran versus warfarin.
Buprenorphine treatment with and without induction was found to decrease costs and utilization in opioid-dependent benefciaries.
Focusing on cost alone could diminish the vital service aspects behind successfully caring for a patient in a specialty pharmacy.
Upcoming Partner Events